JP4611444B2 - ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール - Google Patents

ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール Download PDF

Info

Publication number
JP4611444B2
JP4611444B2 JP2009545240A JP2009545240A JP4611444B2 JP 4611444 B2 JP4611444 B2 JP 4611444B2 JP 2009545240 A JP2009545240 A JP 2009545240A JP 2009545240 A JP2009545240 A JP 2009545240A JP 4611444 B2 JP4611444 B2 JP 4611444B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
indazole
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009545240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010515715A5 (OSRAM
JP2010515715A (ja
Inventor
ジョーンズ，フィリップ
マリア オントリア，オントリア，ヘスス
スカルペリ，リタ
シュルツ−ファデムレヒト，カルステン
Original Assignee
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39246752&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4611444(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0700432.8A external-priority patent/GB0700432D0/en
Application filed by イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー filed Critical イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー
Publication of JP2010515715A publication Critical patent/JP2010515715A/ja
Publication of JP2010515715A5 publication Critical patent/JP2010515715A5/ja
Application granted granted Critical
Publication of JP4611444B2 publication Critical patent/JP4611444B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2009545240A 2007-01-10 2008-01-08 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール Active JP4611444B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0700432.8A GB0700432D0 (en) 2007-01-10 2007-01-10 Therapeutic compounds
US92131007P 2007-04-02 2007-04-02
PCT/GB2008/050018 WO2008084261A1 (en) 2007-01-10 2008-01-08 Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors

Publications (3)

Publication Number Publication Date
JP2010515715A JP2010515715A (ja) 2010-05-13
JP2010515715A5 JP2010515715A5 (OSRAM) 2010-06-24
JP4611444B2 true JP4611444B2 (ja) 2011-01-12

Family

ID=39246752

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545240A Active JP4611444B2 (ja) 2007-01-10 2008-01-08 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール

Country Status (31)

Country Link
US (1) US8071623B2 (OSRAM)
EP (4) EP2109608B1 (OSRAM)
JP (1) JP4611444B2 (OSRAM)
KR (1) KR101591656B1 (OSRAM)
AR (1) AR064777A1 (OSRAM)
AU (1) AU2008204380B2 (OSRAM)
BR (1) BRPI0806245B1 (OSRAM)
CA (1) CA2674436C (OSRAM)
CL (1) CL2008000046A1 (OSRAM)
CO (1) CO6210732A2 (OSRAM)
CY (3) CY1111584T1 (OSRAM)
DK (1) DK2805945T3 (OSRAM)
DO (1) DOP2009000170A (OSRAM)
EA (1) EA016079B1 (OSRAM)
EC (1) ECSP099484A (OSRAM)
GE (1) GEP20115337B (OSRAM)
GT (1) GT200900190A (OSRAM)
HR (2) HRP20110447T1 (OSRAM)
HU (1) HUS1800022I1 (OSRAM)
IL (1) IL199264A (OSRAM)
LT (1) LTC2109608I2 (OSRAM)
MA (1) MA31554B1 (OSRAM)
MX (1) MX2009007200A (OSRAM)
NL (1) NL300937I2 (OSRAM)
NO (1) NO2018016I1 (OSRAM)
PL (3) PL2805945T3 (OSRAM)
RS (2) RS58936B1 (OSRAM)
SI (1) SI2805945T1 (OSRAM)
SV (1) SV2009003321A (OSRAM)
TN (1) TN2009000286A1 (OSRAM)
WO (1) WO2008084261A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011509252A (ja) * 2008-01-08 2011-03-24 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7559282B2 (en) * 2002-10-16 2009-07-14 Robert Austin Monorail sortation system
RU2447889C2 (ru) * 2005-07-18 2012-04-20 Бипар Сайенсиз, Инк. Способ лечения рака (варианты)
US20090275619A1 (en) * 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
CA2662517A1 (en) 2006-09-05 2008-03-13 Jerome Moore Treatment of cancer
EP2118062A1 (en) 2007-01-10 2009-11-18 F. Hoffmann-Roche AG Sulfonamide derivatives as chymase inhibitors
SG185952A1 (en) 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
WO2010011927A1 (en) 2008-07-25 2010-01-28 Noventis, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
AU2010210636A1 (en) * 2009-02-04 2011-09-22 Bipar Sciences, Inc. Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
US8425662B2 (en) 2010-04-02 2013-04-23 Battelle Memorial Institute Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies
CA2806208C (en) 2010-07-22 2018-02-13 Zishan Haroon Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
US9073893B2 (en) 2011-07-26 2015-07-07 Nerviano Medical Sciences S.R.L. 3-Oxo-2,3-dihydro-1H-indazole-4-carboxamide derivatives as PARP-1 inhibitors
CN105419379B (zh) 2011-09-26 2018-11-20 日东电工株式会社 用于提高的日光采集效率的高荧光且光稳定性生色团
WO2013052381A2 (en) 2011-10-05 2013-04-11 Nitto Denko Corporation Wavelength conversion film having pressure sensitive adhesive layer to enhance solar harvesting efficiency
US20140335074A1 (en) 2011-12-13 2014-11-13 Buck Institute For Research On Aging Methods for improving medical therapies
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
AR091731A1 (es) * 2012-07-19 2015-02-25 Merck Sharp & Dohme Antagonistas del receptor de mineralocorticoides
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
WO2014088983A1 (en) * 2012-12-07 2014-06-12 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
US9738915B2 (en) 2012-12-07 2017-08-22 Merck Sharp & Dohme Corp. Biocatalytic transamination process
TWI522352B (zh) * 2013-10-12 2016-02-21 貝達藥業股份有限公司 醯胺基取代的吲唑衍生物類聚（ａｄｐ－核糖）聚合酶抑制劑
EP3157566B1 (en) 2014-06-17 2019-05-01 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
SMT202400420T1 (it) 2015-04-01 2024-11-15 Anaptysbio Inc Anticorpi diretti contro la proteina dell’immunoglobulina delle cellule t e della mucina 3 (tim-3)
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
ES2766853T3 (es) 2015-12-14 2020-06-15 Fmc Corp Pesticidas de azol bicíclico sustituido con heterociclo
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CA3029671C (en) 2016-06-29 2023-08-15 Tesaro, Inc. Methods of treating ovarian cancer
SI3490560T1 (sl) 2016-07-29 2025-04-30 Janssen Pharmaceutica, N.V. Niraparib za uporabo pri metodi zdravljenja raka prostate
MA46724A (fr) 2016-11-01 2021-04-21 Anaptysbio Inc Anticorps dirigés contre la mort programmée 1 (pd -1)
KR20190098741A (ko) 2016-11-01 2019-08-22 아납티스바이오, 아이엔씨. T 세포 면역글로불린 및 뮤신 단백질 3(tim-3)에 대한 항체
CN108201537A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种尼拉帕尼缓控释药物组合物及其用途
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
MA47208A (fr) 2017-01-09 2019-11-13 Tesaro Inc Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA47206A (fr) 2017-01-09 2019-11-13 Tesaro Inc Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018136010A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018183354A1 (en) 2017-03-27 2018-10-04 Tesaro, Inc. Niraparib compositions
US11384062B2 (en) 2017-04-04 2022-07-12 Combiphos Catalysts, Inc. Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
JOP20190244A1 (ar) 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
ES2926255T3 (es) * 2017-04-24 2022-10-24 Tesaro Inc Métodos de fabricación de niraparib
MX2019012793A (es) 2017-04-27 2020-02-13 Tesaro Inc Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.
CN110831580A (zh) 2017-05-09 2020-02-21 特沙诺有限公司 用于治疗癌症的组合疗法
AU2018270112A1 (en) 2017-05-18 2019-12-12 Tesaro, Inc. Combination therapies for treating cancer
CN109081828B (zh) 2017-06-14 2021-03-26 上海时莱生物技术有限公司 聚(adp-核糖)聚合酶抑制剂、制备方法及用途
US11858879B2 (en) 2017-06-23 2024-01-02 City Of Hope PARG inhibitors and method of use thereof
HUE062956T2 (hu) 2017-08-14 2023-12-28 Teva Pharmaceuticals Int Gmbh Eljárások niraparib és köztitermékei elõállítására
JP7269227B2 (ja) 2017-09-26 2023-05-08 テサロ， インコーポレイテッド ニラパリブ処方物
CA3076515A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. Combination therapies for treating cancer
CN111182923A (zh) 2017-10-06 2020-05-19 特沙诺有限公司 组合疗法及其用途
WO2019083456A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER FOR NORMALIZING ANGIOGENESIS IN A CANCER MASS
WO2019083457A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS MUTATION OF THE BETA-CATENIN PATHWAY
WO2019083455A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS PRESENTING HER1, HER2 AND / OR HER3-ACTIVATED HERC-RECEPTOR CANCER CELLS
WO2019083458A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR THE TREATMENT OF CANCER TO REDUCE HYPOXIA
CR20200291A (es) 2017-12-07 2020-11-18 Reven Ip Holdco Llc Composiciones y métodos para el tratamiento de enfermedades metabólicas
CA3087060A1 (en) 2017-12-27 2019-07-04 Tesaro, Inc. Methods of treating cancer
BR112020013672A2 (pt) 2018-01-05 2020-12-01 Cybrexa 1, Inc. compostos, composições, e métodos para tratamento de doenças que envolvem tecidos afetados por ácidos ou hipoxia
WO2019152989A1 (en) 2018-02-05 2019-08-08 Tesaro, Inc Pediatric niraparib formulations and pediatric treatment methods
WO2019196812A1 (zh) * 2018-04-09 2019-10-17 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
TWI852940B (zh) 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
CN113330007A (zh) 2018-10-03 2021-08-31 特沙诺有限公司 尼拉帕利游离碱的晶体形式
WO2020072860A1 (en) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Niraparib solid state form
KR20210097124A (ko) 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
US20220319704A1 (en) 2019-05-06 2022-10-06 Tesaro, Inc. Methods for characterizing and treating a cancer type using cancer images
CN110156751B (zh) * 2019-05-28 2022-01-18 江苏食品药品职业技术学院 一种制备尼拉帕尼及其中间体的新方法
BR112021025105A2 (pt) * 2019-06-12 2022-03-15 Reven Ip Holdco Llc Métodos e composições para melhorar os resultados de pacientes com câncer
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
JP7675060B2 (ja) 2019-07-10 2025-05-12 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
AU2021267146A1 (en) * 2020-05-08 2023-01-19 Janssen Pharmaceutica Nv Treatments of prostate cancer with combinations of abiraterone acetate and niraparib
PE20240119A1 (es) 2021-01-08 2024-01-22 Cybrexa 2 Inc Proceso para preparar un resto enlazador de conjugados
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
EP4319729A4 (en) * 2021-04-09 2025-02-26 Cardiff Oncology, Inc. CANCER TREATMENT WITH PARP INHIBITORS AND PLK1 INHIBITORS
US20240325369A1 (en) 2021-07-19 2024-10-03 Janssen Pharmaceutica Nv Treatment of metastatic castration-resistant prostate cancer with niraparib
JP2025506402A (ja) 2022-02-04 2025-03-11 ヤンセン ファーマシューティカ エヌ．ベー． 転移性去勢抵抗性前立腺癌及びｈｒｒ変化を有する患者における臨床アウトカムを改善するためのニラパリブ及び酢酸アビラテロン＋プレドニゾン
CN119156216A (zh) 2022-02-15 2024-12-17 特沙诺有限公司 尼拉帕尼用于治疗脑癌的用途
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
EP4532493A1 (en) 2022-06-01 2025-04-09 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
WO2024054898A1 (en) * 2022-09-08 2024-03-14 Cardiff Oncology, Inc. Onvansertib and parp inhibitor combination
EP4583983A1 (en) 2022-09-11 2025-07-16 Cardiff Oncology, Inc. Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
WO2024142096A1 (en) * 2022-12-29 2024-07-04 Dr. Reddy’S Laboratories Limited Process for preparation of niraparib tosylate and its intermediates
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2024238587A1 (en) 2023-05-17 2024-11-21 Tesaro, Inc. Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer
WO2025017711A1 (en) * 2023-07-20 2025-01-23 Natco Pharma Limited An improved process for the preparation of niraparib tosylate monohydrate
CN121443291A (zh) 2023-08-02 2026-01-30 詹森药业有限公司 尼拉帕尼和阿比特龙组合用于治疗转移性去势抵抗性前列腺癌
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (345)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
US2789118A (en) 1956-03-30 1957-04-16 American Cyanamid Co 16-alpha oxy-belta1, 4-pregnadienes
US2990401A (en) 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3048581A (en) 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3749712A (en) 1970-09-25 1973-07-31 Sigma Tau Ind Farmaceuti Triamcinolone acetonide esters and process for their preparation
SE378109B (OSRAM) 1972-05-19 1975-08-18 Bofors Ab
US3996359A (en) 1972-05-19 1976-12-07 Ab Bofors Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
SE378110B (OSRAM) 1972-05-19 1975-08-18 Bofors Ab
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4294926A (en) 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JPS5889191A (ja) 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4911165A (en) 1983-01-12 1990-03-27 Ethicon, Inc. Pliabilized polypropylene surgical filaments
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4885314A (en) 1987-06-29 1989-12-05 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4782084A (en) 1987-06-29 1988-11-01 Merck & Co., Inc. HMG-COA reductase inhibitors
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5118853A (en) 1988-10-13 1992-06-02 Sandoz Ltd. Processes for the synthesis of 3-disubstituted aminoacroleins
US5290946A (en) 1988-10-13 1994-03-01 Sandoz Ltd. Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
WO1990005525A1 (en) 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US4929437A (en) 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5164372A (en) 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
US5189164A (en) 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
IE903957A1 (en) 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
FR2654726B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone et leur preparation.
FR2654725B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB8929070D0 (en) 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
UA41251C2 (uk) 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5321032A (en) 1990-02-15 1994-06-14 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds and pharmaceutical compositions thereof
US5420245A (en) 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
GB9011833D0 (en) 1990-05-25 1990-07-18 Collins Mary K L Inhibition of viral infection
US5451586A (en) 1990-06-01 1995-09-19 Pfizer Inc. 3-amino-2-aryl quinuclidines
CA2086434C (en) 1990-07-23 1998-09-22 John A. Lowe, Iii Quinuclidine derivatives
ES2071334T3 (es) 1990-09-28 1995-06-16 Pfizer Analogos de anillos fusionados de nitrogeno conteniendo heterociclos no aromaticos.
GB9023116D0 (en) 1990-10-24 1990-12-05 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
ATE129409T1 (de) 1990-12-21 1995-11-15 Fujisawa Pharmaceutical Co Neue verwendung von peptidderivat.
CA2100163A1 (en) 1991-01-10 1992-07-11 John A. Lowe, Iii N-alkyl quinuclidinium salts
ATE154354T1 (de) 1991-02-11 1997-06-15 Merck Sharp & Dohme Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung
ES2065175T3 (es) 1991-03-01 1995-02-01 Pfizer Derivados de 1-azabiciclo(3.2.2)nonan-3-amina.
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2106200C (en) 1991-03-26 1996-11-19 Terry J. Rosen Stereoselective preparation of substituted piperidines
FR2677361A1 (fr) 1991-06-04 1992-12-11 Adir Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2676053B1 (fr) 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676055B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676447B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole et leur preparation.
FR2676442B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676446B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676443B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole et leur preparation.
PL172069B1 (pl) 1991-05-22 1997-07-31 Pfizer Sposób wytwarzania nowych pochodnych podstawionej 3-aminochinuklidyny PL PL PL PL PL
US5292726A (en) 1991-05-22 1994-03-08 Merck & Co., Inc. N,N-diacylpiperazines
JPH0733386B2 (ja) 1991-05-31 1995-04-12 フアイザー・インコーポレイテツド キヌクリジン誘導体
GB9113219D0 (en) 1991-06-19 1991-08-07 Fujisawa Pharmaceutical Co Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
SK282203B6 (sk) 1991-06-20 2001-12-03 Pfizer Inc. Fluoroalkoxybenzylamínové deriváty heterocyklov obsahujúcich dusík, spôsob ich prípravy, medziprodukty, spôsob prípravy medziproduktov, použitie a farmaceutický prostriedok
TW202432B (OSRAM) 1991-06-21 1993-03-21 Pfizer
US5288730A (en) 1991-06-24 1994-02-22 Merck Sharp & Dohme Limited Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
CA2110514A1 (en) 1991-07-05 1993-01-21 Raymond Baker Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
EP0536817A1 (en) 1991-07-05 1993-04-14 MERCK SHARP & DOHME LTD. Azabicyclic compounds as tachykinin antagonists
ATE133657T1 (de) 1991-07-05 1996-02-15 Merck Sharp & Dohme Aromatische verbindungen, diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische anwendung
US5495047A (en) 1991-07-10 1996-02-27 Merck, Sharp & Dohme (Ltd.) Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
CA2110725A1 (en) 1991-07-10 1993-01-21 Andrew P. Owens Aromatic compounds, compositions containing them and their use in therapy
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
EP0600952B1 (en) 1991-08-20 1996-04-17 MERCK SHARP & DOHME LTD. Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
EP1082959A1 (en) 1991-09-20 2001-03-14 Glaxo Group Limited NK1 Antagonists for the treatment of depression
CA2118704C (en) 1991-09-26 1997-01-21 John A. Lowe, Iii Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
US5652260A (en) 1991-10-22 1997-07-29 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compound useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
JP2553020B2 (ja) 1991-11-07 1996-11-13 吉富製薬株式会社 キヌクリジン化合物およびその医薬用途
ES2111650T3 (es) 1991-11-12 1998-03-16 Pfizer Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
HU217629B (hu) 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
GB9200535D0 (en) 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
GB9201179D0 (en) 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
US5328927A (en) 1992-03-03 1994-07-12 Merck Sharpe & Dohme, Ltd. Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them
JP2656702B2 (ja) 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
FR2689888B1 (fr) 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
CA2133077A1 (en) 1992-04-15 1993-10-28 Raymond Baker Azacyclic compounds
GB2266529A (en) 1992-05-01 1993-11-03 Merck Sharp & Dohme Tetrahydroisoquinoline derivatives
JP2757234B2 (ja) 1992-05-18 1998-05-25 ファイザー インク． Ｐ物質拮抗薬としての架橋アザ二環式誘導体
GB9211193D0 (en) 1992-05-27 1992-07-08 Merck Sharp & Dohme Therapeutic agents
US5637699A (en) 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
CA2099233A1 (en) 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
AU4713293A (en) 1992-07-13 1994-01-31 Merck Sharp & Dohme Limited Heterocyclic amide derivatives as tachykinin derivatives
EP1251170A3 (en) 1992-07-17 2002-10-30 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of NF-kappaB dependent animal diseases
GB2268931A (en) 1992-07-22 1994-01-26 Merck Sharp & Dohme Azabicyclic tachykinin-receptor antagonists
DE69322275T2 (de) 1992-07-28 1999-06-24 Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire Azazyklische verbindungen
GB2269170A (en) 1992-07-29 1994-02-02 Merck Sharp & Dohme Azatricyclic tachykinin antagonists
AU4718093A (en) 1992-07-31 1994-03-03 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
JPH07506379A (ja) 1992-08-04 1995-07-13 ファイザー・インコーポレーテッド 物質ｐ受容体アンタゴニストとしての３−ベンジルアミノ−２−フェニル−ピペリジン
GB9216911D0 (en) 1992-08-10 1992-09-23 Merck Sharp & Dohme Therapeutic agents
DK0655055T3 (da) 1992-08-13 2001-01-02 Warner Lambert Co Tachykininantagonister
AU4224993A (en) 1992-08-19 1994-03-15 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
EP0585913B1 (en) 1992-09-04 1997-12-29 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
US5563161A (en) 1992-09-10 1996-10-08 Merck Sharp & Dohme Ltd. Alcohols and ethers with aromatic substituents as tachykinin-antagonists
GB9220286D0 (en) 1992-09-25 1992-11-11 Merck Sharp & Dohme Therapeutic agents
JP2656699B2 (ja) 1992-10-21 1997-09-24 ファイザー製薬株式会社 置換ベンジルアミノキヌクリジン
GB9222262D0 (en) 1992-10-23 1992-12-09 Merck Sharp & Dohme Therapeutic agents
GB9222486D0 (en) 1992-10-26 1992-12-09 Merck Sharp & Dohme Therapeutic agents
AU678409B2 (en) 1992-10-28 1997-05-29 Merck Sharp & Dohme Limited 4-arylmethyloxymethyl piperidines as tachykinin antagonists
JP2656700B2 (ja) 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
AU5342894A (en) 1992-10-30 1994-05-24 Merck Sharp & Dohme Limited Tachykinin antagonists
AU676489B2 (en) 1992-11-12 1997-03-13 Pfizer Inc. Quinuclidine derivative as substance P antagonist
US5261188A (en) 1992-11-23 1993-11-16 The Standard Products Company Belt weatherstrip with bulb
PT675886E (pt) 1992-12-10 2000-12-29 Pfizer Heterociclos nao aromaticos com substituintes aminometileno e sua utilizacao como antagonistas da substancia p
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0673367A1 (en) 1992-12-14 1995-09-27 MERCK SHARP & DOHME LTD. 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
EP0604181A1 (en) 1992-12-21 1994-06-29 Eli Lilly And Company Antitumor compositions and method of treatment
GB9226581D0 (en) 1992-12-21 1993-02-17 Merck Sharp & Dohme Therapeutic agents
GB9300051D0 (en) 1993-01-04 1993-03-03 Merck Sharp & Dohme Therapeutic agents
EP0759432A1 (en) 1993-01-15 1997-02-26 G.D. Searle & Co. Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a skin-related condition
EP0610793A1 (en) 1993-02-08 1994-08-17 Takeda Chemical Industries, Ltd. Tetracyclic morpholine derivatives and their use or analgesics
EP0683767B1 (en) 1993-02-18 1998-06-03 MERCK SHARP & DOHME LTD. Azacyclic compounds, compositions containing them and their use as tachykinin antagonists
US5674889A (en) 1993-02-22 1997-10-07 Merck, Sharp & Dohme, Ltd. Aromatic compounds, compositions containing them and their use in therapy
WO1994019357A1 (en) 1993-02-23 1994-09-01 Merrell Dow Pharmaceuticals Inc. Farnesyl:protein transferase inhibitors as anticancer agents
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5688806A (en) 1993-03-04 1997-11-18 Pfizer Inc. Spiroazacyclic derivatives as substance P antagonists
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
US5496833A (en) 1993-04-13 1996-03-05 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
ES2110761T3 (es) 1993-05-06 1998-02-16 Merrell Pharma Inc Pirrolidin-3-il-alquil-piperidinas sustituidas utiles como antagonistas de la taquiquinina.
AU6909194A (en) 1993-05-14 1994-12-12 Board Of Regents, The University Of Texas System Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
US5602098A (en) 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase
IL109646A0 (en) 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
JPH08511522A (ja) 1993-06-07 1996-12-03 メルク エンド カンパニー インコーポレーテッド ニューロキニンアンタゴニストとしてのスピロ置換アザ環
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
EP0634402A1 (en) 1993-07-14 1995-01-18 Takeda Chemical Industries, Ltd. Isochinolinone derivatives, their production and use
CA2167198C (en) 1993-07-15 1999-03-16 Kunio Satake Benzylaminoquinuclidines
GB9315808D0 (en) 1993-07-30 1993-09-15 Merck Sharp & Dohme Therapeutic agents
TW365603B (en) 1993-07-30 1999-08-01 Rhone Poulenc Rorer Sa Novel perhydroisoindole derivatives, their preparation and pharmaceutical compositions which contain them
GB9317987D0 (en) 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds
DK0719253T3 (da) 1993-09-17 2004-07-26 Pfizer 3-amino-5-carboxy-substituerede piperidiner og 3-amino-4-carboxy-substituerede pyrrolidiner som tachykininantagonister
WO1995007908A1 (en) 1993-09-17 1995-03-23 Pfizer Inc. Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds
EP0670314A4 (en) 1993-09-22 1996-04-10 Kyowa Hakko Kogyo Kk FARNESYL TRANSFERASE INHIBITORS.
IS4208A (is) 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US5661152A (en) 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
HUT76066A (en) 1993-10-15 1997-06-30 Schering Corp Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases, pharmaceutical compositions containing them and process for producing them
NZ275646A (en) 1993-10-15 1998-02-26 Schering Corp Tricyclic sulphonamide derivatives and medicaments
US5719148A (en) 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
JPH09504295A (ja) 1993-10-25 1997-04-28 パーク・デイビス・アンド・カンパニー タンパク質：ファルネシルトランスフェラーゼの置換されたテトラ‐およびペンタペプチド阻害剤
AU7947594A (en) 1993-10-27 1995-05-22 Merck Sharp & Dohme Limited Substituted amides as tachykinin antagonists
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
DE69417012T2 (de) 1993-11-04 1999-10-07 Abbott Laboratories, Abbott Park Cyclobutan-derivate als inhibitoren der squalen-synthetase und der protein-farnesyltransferase
EP0730605A1 (en) 1993-11-05 1996-09-11 Warner-Lambert Company Substituted di- and tripeptide inhibitors of protein:farnesyl transferase
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
IT1271462B (it) 1993-12-03 1997-05-28 Menarini Farma Ind Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
US5484799A (en) 1993-12-09 1996-01-16 Abbott Laboratories Antifungal dorrigocin derivatives
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
AU1339795A (en) 1993-12-21 1995-07-10 Eli Lilly And Company Non-peptide tachykinin receptor antagonists
US5854239A (en) 1993-12-29 1998-12-29 Pfizer Inc. Diazabicyclic neuokinin antagonists
ATE364606T1 (de) 1993-12-29 2007-07-15 Merck Sharp & Dohme Substituierte morpholinderivate und ihre verwendung als arzneimittel
CA2180746A1 (en) 1994-01-13 1995-07-20 Raymond Baker Gem-disubstituted azacyclic tachykinin antagonists
JPH09508376A (ja) 1994-01-28 1997-08-26 メルク シヤープ エンド ドーム リミテツド アラルキル置換アザシクロ系の治療薬
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
GB9402688D0 (en) 1994-02-11 1994-04-06 Merck Sharp & Dohme Therapeutic agents
US5610165A (en) 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
WO1995024612A1 (de) 1994-03-07 1995-09-14 International Business Machines Corporation Verfahren und vorrichtung zur schnellen interpolation von zwischenwerten aus periodischen phasenverschobenen signalen und zur erkennung von defekten in einem drehkörper
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
FI963597L (fi) 1994-03-15 1996-11-14 Eisai Co Ltd Isoprenyylitransferaasi-inhibiittoreita
FR2718136B1 (fr) 1994-03-29 1996-06-21 Sanofi Sa Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
RU95104898A (ru) 1994-03-31 1996-12-27 Бристоль-Мейерз Сквибб Компани (US) Имидазолсодержащие ингибиторы фарнезид-протеинтрансферазы, способ лечения связанных с ней заболеваний
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
ZA953311B (en) 1994-04-29 1996-10-24 Lilly Co Eli Non-peptidyl tachykinin receptor antagonists
JPH10500944A (ja) 1994-05-05 1998-01-27 メルク シヤープ エンド ドーム リミテツド モルホリン誘導体及びタキキニンのアンタゴニストとしてのそれらの使用
JPH09512806A (ja) 1994-05-07 1997-12-22 ベーリンガー インゲルハイム コマンディトゲゼルシャフト 新規なアミノ酸誘導体、その製造方法及びこれらの化合物を含む医薬組成物（ｉｉ）
US5510510A (en) 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US5563255A (en) 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
CA2187531A1 (en) 1994-06-06 1995-12-14 David Christopher Horwell Tachykinin (nk1) receptor antagonists
WO1995034535A1 (fr) 1994-06-10 1995-12-21 Rhone-Poulenc Rorer S.A. Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
EP0686629A3 (en) 1994-06-10 1999-02-10 Eli Lilly And Company Cyclohexyl tachykinine receptor antagonists
US5571792A (en) 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
NZ289652A (en) 1994-07-12 1998-05-27 Lilly Co Eli (r)-3-(1h-indol-3-yl)-1-[n-(2-methoxybenzyl)acetylamino]-2-[n-(2-(4-( piperidin-1-yl)piperidin-1-yl)acetyl)amino]propane dihydrochloride trihydrate; non-peptidyl tachykinin receptor antagonistic medicaments
CA2154116A1 (en) 1994-07-22 1996-01-23 Philip Arthur Hipskind 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists
GB9415996D0 (en) 1994-08-08 1994-09-28 Merck Sharp & Dohme Therapeutic agents
GB9415997D0 (en) 1994-08-08 1994-09-28 Merck Sharp & Dohme Therapeutic agents
TW432061B (en) 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
WO1996005529A1 (en) 1994-08-09 1996-02-22 Micron Optics, Inc. Temperature compensated fiber fabry-perot filters
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
ATE188464T1 (de) 1994-08-11 2000-01-15 Banyu Pharma Co Ltd Substituierte amidderivate
AU691331B2 (en) 1994-08-12 1998-05-14 Myriad Genetics, Inc. Method for diagnosing a predisposition for breast and ovarian cancer
DK0705903T3 (da) 1994-08-12 2001-08-27 Myriad Genetics Inc Mutationer i det 17q-koblede bryst- og ovariecancerprædisponeringen
AU3192495A (en) 1994-08-12 1996-03-07 Banyu Pharmaceutical Co., Ltd. N,n-disubstituted amic acid derivative
PT777659E (pt) 1994-08-15 2001-09-28 Merck Sharp & Dohme Derivados de morfolina e sua utilizacao como agentes terapeuticos
DE4429506B4 (de) 1994-08-19 2007-09-13 Degussa Gmbh Verfahren zur Extraktion natürlicher Carotinoid-Farbstoffe
DE4429653C2 (de) 1994-08-20 1997-04-03 Anton Dr More Konverter und Verfahren zum Frischen von Metallschmelzen insbesondere von Roheisen zu Stahl
DE69508093T2 (de) 1994-08-25 1999-07-15 Merrell Pharmaceuticals Inc., Cincinnati, Ohio Substituierte piperidine für die behandlung von allergischen krankheiten
ES2107118T3 (es) 1994-08-29 1997-11-16 Akzo Nobel Nv Procedimiento para la preparacion de diesteres cuaternarios.
GB9417956D0 (en) 1994-09-02 1994-10-26 Merck Sharp & Dohme Therapeutic agents
GB9418545D0 (en) 1994-09-15 1994-11-02 Merck Sharp & Dohme Therapeutic agents
US5457107A (en) 1994-09-16 1995-10-10 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US5935951A (en) 1994-09-30 1999-08-10 Novartis Finance Corporation 1-acyl-4-aliphatylaminopiperidine compounds
TW397825B (en) 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
FR2725986B1 (fr) 1994-10-21 1996-11-29 Adir Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0709375B1 (en) 1994-10-25 2005-05-18 AstraZeneca AB Therapeutic heterocycles
GB9421709D0 (en) 1994-10-27 1994-12-14 Zeneca Ltd Therapeutic compounds
EP0740853B1 (en) 1994-11-22 1999-01-13 Koninklijke Philips Electronics N.V. Semiconductor device with a carrier body on which a substrate with a semiconductor element is fastened by means of a glue layer and on which a pattern of conductor tracks is fastened
EP0714891A1 (en) 1994-11-22 1996-06-05 Eli Lilly And Company Heterocyclic tachykinin receptor antagonists
FR2727411B1 (fr) 1994-11-30 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2204144A1 (en) 1994-12-09 1996-06-13 Francis J. Tinney Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
IL116323A0 (en) 1994-12-13 1996-03-31 Sandoz Ag Tachykinin antagonists their preparation and pharmaceutical compositions containing them
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
GB9426103D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Therapeutic agents
BR9606896A (pt) 1995-01-09 1997-10-21 Magla Int Ltd Impressão de imagem resistente á água em superficies de látex
ATE279406T1 (de) 1995-01-12 2004-10-15 Glaxo Group Ltd Piperidinderivate mit tachykinin-antagonistischer wirkung
AU4915796A (en) 1995-01-12 1996-07-31 University Of Pittsburgh Inhibitors of prenyl transferases
FR2729390A1 (fr) 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2729951B1 (fr) 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2730492B1 (fr) 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2730491B1 (fr) 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
GB9505492D0 (en) 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9505491D0 (en) 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
US5554641A (en) 1995-03-20 1996-09-10 Horwell; David C. Nonpeptides as tachykinin antagonists
GB9505692D0 (en) 1995-03-21 1995-05-10 Glaxo Group Ltd Chemical compounds
US5684013A (en) 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5700806A (en) 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
NO309272B1 (no) 1995-03-24 2001-01-08 Takeda Chemical Industries Ltd Cykliske forbindelser, preparater inneholdende forbindelsene samt mellomprodukter for fremstilling av forbindelsene
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
US5891872A (en) 1995-04-07 1999-04-06 Schering Corporation Tricyclic compounds
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117805A0 (en) 1995-04-07 1996-08-04 Schering Corp Carbonyl piperazinyl and piperidinyl compounds
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
WO1996032385A1 (en) 1995-04-13 1996-10-17 Hoechst Marion Roussel, Inc. Novel substituted piperazine derivatives having tachykinin receptor antagonists activity
US5831115A (en) 1995-04-21 1998-11-03 Abbott Laboratories Inhibitors of squalene synthase and protein farnesyltransferase
IL118101A0 (en) 1995-05-03 1996-09-12 Abbott Lab Inhibitors of farnesyltransferase
HUP9900822A3 (en) 1995-05-25 1999-11-29 Fujisawa Pharmaceutical Co Piperazine derivatives, process for producing them, pharmaceutical compositions containing them and method for treating tachykinin-mediated diseases
AU6034296A (en) 1995-06-16 1997-01-15 Warner-Lambert Company Tricyclic inhibitors of protein farnesyltransferase
GB9513117D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
GB9513118D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
GB9513121D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
EP0840732B1 (en) 1995-07-07 2001-03-07 Pfizer Inc. Substituted benzolactam compounds as substance p antagonists
FR2736641B1 (fr) 1995-07-10 1997-08-22 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
AT402617B (de) 1995-07-11 1997-07-25 Datacon Schweitzer & Zeindl Gm Anlage zum automatisierten, hermetischen anlage zum automatisierten, hermetischen verschliessen von gehäusen verschliessen von gehäusen
FR2736638B1 (fr) 1995-07-12 1997-08-22 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
CH690163A5 (fr) 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
CA2225465A1 (en) 1995-08-02 1997-02-13 Newcastle University Ventures Limited Benzimidazole compounds
TW340842B (en) 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
US6020343A (en) 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
EP0858444A4 (en) 1995-10-18 1999-12-01 Merck & Co Inc Cyclopentyl tachykinin receptor antagonists
DE19541283A1 (de) 1995-11-06 1997-05-07 Boehringer Ingelheim Kg Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
WO1997017070A1 (en) 1995-11-06 1997-05-15 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
GB9523244D0 (en) 1995-11-14 1996-01-17 Merck Sharp & Dohme Therapeutic agents
PT1186606E (pt) 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf Derivados do epotilone sua preparacao e utilizacao
AU704139B2 (en) 1995-11-22 1999-04-15 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000500760A (ja) 1995-11-23 2000-01-25 メルク シヤープ エンド ドーム リミテツド スピロピペリジン誘導体およびタキキニン拮抗薬としてのその使用
GB9524157D0 (en) 1995-11-25 1996-01-24 Pfizer Ltd Therapeutic agents
HU224225B1 (hu) 1995-12-01 2005-06-28 Sankyo Co. Ltd. Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására
AU711142B2 (en) 1995-12-08 1999-10-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives
GB9525296D0 (en) 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
WO1997023478A1 (en) 1995-12-22 1997-07-03 Schering Corporation Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
WO1997026246A1 (en) 1996-01-16 1997-07-24 Warner-Lambert Company Substituted histidine inhibitors of protein farnesyltransferase
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
WO1997038665A2 (en) 1996-04-03 1997-10-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DK0892791T3 (da) 1996-04-12 2003-06-23 Searle & Co N-[[4-(5-methyl-3-phenylisoxazol-4-yl]-phenyl]-sulfonylpropylamid og dets natriumsalt som prodrugs for COX-2-inhibitorer
CZ376498A3 (cs) 1996-05-22 1999-02-17 Warner-Lambert Company Inhibitory proteinové farnesyl fransferázy
JP2000514456A (ja) 1996-07-15 2000-10-31 ブリストル―マイヤーズ・スクイブ・カンパニー ファルネシルプロテイントランスフェラーゼのチアジオキソベンゾジアゼピン阻害剤
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
EP1886677A1 (en) 1996-07-26 2008-02-13 Susan P. Perrine Use of an inducing agent for the treatment of blood, viral and cellular disorders
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP0951285A1 (en) 1996-12-30 1999-10-27 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP1003374A4 (en) 1996-12-30 2000-05-31 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
JP2002515488A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法
ES2200594T3 (es) 1998-10-30 2004-03-01 Lonza Ag Procedimiento para la preparacion de 4-((2`,5`-diamino-6`-halogenopirimidin-4il)amino)-ciclopent-2-enilmetanoles.
JP2002528531A (ja) 1998-11-03 2002-09-03 ビーエーエスエフ アクチェンゲゼルシャフト 置換２−フェニルベンズイミダゾール、その製造法および使用
CA2350734C (en) 1998-11-17 2006-10-10 Basf Aktiengesellschaft 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
SI1133477T1 (en) 1998-11-27 2004-06-30 Abbott Gmbh & Co. Kg Substituted benzimidazoles and their use as parp inhibitors
EP1151002A4 (en) 1999-01-29 2002-05-02 Imclone Systems Inc KDR-SPECIFIC ANTIBODIES AND USES THEREOF
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
WO2001021615A1 (fr) 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
NZ518480A (en) 1999-10-27 2004-02-27 Cytokinetics Inc Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
ATE372337T1 (de) 2000-02-01 2007-09-15 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
WO2002057244A1 (en) 2001-01-19 2002-07-25 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US20040132830A1 (en) 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
WO2002068407A1 (en) 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole compound
EP1379251B1 (en) 2001-04-10 2008-07-09 Merck & Co., Inc. Inhibitors of akt activity
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US6958334B2 (en) 2001-04-10 2005-10-25 Merck & Co., Inc. Inhibitors of Akt activity
WO2002083675A2 (en) 2001-04-10 2002-10-24 Merck Sharp & Dohme Limited Inhibitors of akt activity
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
WO2003013526A1 (en) 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
JP2005511581A (ja) 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
ATE447577T1 (de) 2001-12-06 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
DE60232994D1 (de) 2001-12-06 2009-08-27 Merck & Co Inc Inhibitoren von mitotischem kinesin
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
EP1463733B1 (en) 2001-12-06 2007-09-05 Merck & Co., Inc. Mitotic kinesin inhibitors
US7244723B2 (en) 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
WO2003105855A1 (en) 2002-01-11 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2473039C (fr) 2002-01-18 2014-09-23 Pierre Fabre Medicament Nouveaux anticorps anti-igf-ir et leurs applications
JPWO2003062234A1 (ja) 2002-01-23 2005-05-19 山之内製薬株式会社 キノキサリン化合物
ATE448207T1 (de) 2002-03-08 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
CA2480800C (en) 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
EP1494676B1 (en) 2002-04-08 2013-05-08 Merck Sharp & Dohme Corp. Fused quinoxaline derivatives as inhibitors of akt activity
JP4394959B2 (ja) 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
JP4451136B2 (ja) 2002-04-08 2010-04-14 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性阻害薬
CA2483627A1 (en) 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
US20050203110A1 (en) 2002-05-23 2005-09-15 Coleman Paul J. Mitotic kinesin inhibitors
US20040034078A1 (en) 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
JP4463679B2 (ja) 2002-06-14 2010-05-19 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
WO2004014861A1 (ja) 2002-08-09 2004-02-19 Kyorin Pharmaceutical Co., Ltd. 4-置換キノリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩
CA2500848A1 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2006516140A (ja) 2002-12-20 2006-06-22 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
CA2508956A1 (en) 2002-12-20 2004-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2006516254A (ja) * 2003-01-06 2006-06-29 イーライ・リリー・アンド・カンパニー Ｐｐａｒモジュレータとしての縮合ヘテロ環誘導体
WO2004087050A2 (en) 2003-03-28 2004-10-14 Merck & Co., Inc. Mitotic kinesin inhibitors
HU0301154D0 (en) 2003-04-28 2003-07-28 Hideg Kalman Dr Pharmaceutical composition
EP1706386A1 (en) * 2003-12-22 2006-10-04 Eli Lilly And Company Bicyclic derivatives as ppar modulators
MXPA06009701A (es) 2004-02-26 2007-03-26 Inotek Pharmaceuticals Corp Derivados de isoquinolina y metodos de uso de los mismos.
MXPA06014933A (es) * 2004-06-30 2007-02-28 Janssen Pharmaceutica Nv Derivados de 2-alquil quinazolinona sustituidos como inhibidores de poli(adp-ribosa) polimerasa-1.
KR20070057859A (ko) 2004-08-26 2007-06-07 쿠도스 파마슈티칼스 리미티드 4-헤테로아릴메틸 치환된 프탈라지논 유도체
WO2006033003A1 (en) 2004-09-22 2006-03-30 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
CN101316834A (zh) * 2005-09-29 2008-12-03 艾博特公司 在2位取代有苯基的1h-苯并咪唑-4-甲酰胺是强效parp抑制剂
ES2342007T3 (es) 2005-11-15 2010-06-30 Abbott Laboratories 1h-benzimidazol-4-carboxamidas sustituidos eficaces como inhibidores de (parp).
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
JP5228237B2 (ja) 2006-05-02 2013-07-03 アボット・ラボラトリーズ 置換１ｈ−ベンゾイミダゾール−４−カルボキサミドは強力なｐａｒｐ阻害薬である
US20090062268A1 (en) * 2007-08-27 2009-03-05 Lead Therapeutics, Inc. Novel inhibitors of poly(adp-ribose)polymerase (parp)
EP2247600A4 (en) * 2008-02-06 2011-09-14 Biomarin Pharm Inc BENZOXAZOLEBOXYLIC ACID AMIDE AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011509252A (ja) * 2008-01-08 2011-03-24 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩

Also Published As

Publication number Publication date
CY1121751T1 (el) 2020-07-31
HUS1800022I1 (hu) 2018-06-28
CA2674436C (en) 2012-07-17
EP2805945B1 (en) 2019-04-03
NL300937I2 (nl) 2019-01-08
PL2336120T3 (pl) 2014-12-31
RS58936B1 (sr) 2019-08-30
SI2805945T1 (sl) 2019-09-30
PL2109608T3 (pl) 2011-08-31
EP2805945A1 (en) 2014-11-26
AR064777A1 (es) 2009-04-22
EP2336120B1 (en) 2014-07-16
AU2008204380A1 (en) 2008-07-17
KR101591656B1 (ko) 2016-02-19
DK2805945T3 (da) 2019-07-15
WO2008084261A1 (en) 2008-07-17
PL2805945T3 (pl) 2019-09-30
EP2336120A1 (en) 2011-06-22
EP2109608B1 (en) 2011-03-23
US8071623B2 (en) 2011-12-06
HRP20190972T1 (hr) 2019-09-20
KR20090097191A (ko) 2009-09-15
NO2018016I2 (no) 2018-05-14
HK1131137A1 (en) 2010-01-15
MX2009007200A (es) 2009-07-15
US20080167345A1 (en) 2008-07-10
CA2674436A1 (en) 2008-07-17
CL2008000046A1 (es) 2008-05-09
SV2009003321A (es) 2010-01-19
ECSP099484A (es) 2009-10-30
GEP20115337B (en) 2011-11-25
HRP20110447T1 (hr) 2011-08-31
IL199264A (en) 2013-06-27
BRPI0806245A2 (pt) 2011-09-06
NO2018016I1 (no) 2018-05-14
CO6210732A2 (es) 2010-10-20
EP3536690A1 (en) 2019-09-11
CY2018014I2 (el) 2018-09-05
LTPA2018009I1 (lt) 2018-05-25
EA200970674A1 (ru) 2010-02-26
EA016079B1 (ru) 2012-01-30
GT200900190A (es) 2010-11-03
CY1111584T1 (el) 2015-10-07
DOP2009000170A (es) 2010-12-31
HK1154386A1 (en) 2012-04-20
CY2018014I1 (el) 2018-09-05
BRPI0806245B1 (pt) 2022-01-25
RS51780B (sr) 2011-12-31
AU2008204380B2 (en) 2013-08-15
LTC2109608I2 (lt) 2019-05-10
MA31554B1 (fr) 2010-08-02
TN2009000286A1 (en) 2010-12-31
EP2109608A1 (en) 2009-10-21
JP2010515715A (ja) 2010-05-13

Similar Documents

Publication Publication Date Title
JP4611444B2 (ja) ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
JP5989965B2 (ja) ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
ES2362214T3 (es) Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp).
JP2010536842A (ja) ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのキノリン−４−オン及び４−オキソジヒドロシンノリン誘導体
HK40006670A (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
HK1154386B (en) Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
HK1131137B (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100428

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20100428

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20100526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20100608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101005

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101013

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131022

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4611444

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131022

Year of fee payment: 3

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250